AMSA On Call
Go Back
  • GSK Takes a Stand on Payments to Physicians…Who’s Next?

    GlaxoSmithKline (GSK) announced that it will make big changes in its marketing practices by no longer paying physicians to promote its products. It is the first (and hopefully not the last) major pharmaceutical company to address some questionable, and unfortunately popular, marketing techniques that have the potential to create conflicts of interest for physicians. Under its new policy, GSK will no longer pay physicians to speak on its behalf to medical professionals at conferences and other events. Its compensation model for pharmaceutical sales representatives will also move away from one focused on physicians’ prescribing habits.

    Though this policy change is significant, it is part of a growing trend to improve transparency of financial relationships between physicians and pharmaceutical and medical device companies. This movement is evident in federal policy--the Physician Payment Sunshine Act’s Open Payments website will publicly disclose industry payments made to physicians and teaching hospitals starting in September 2014--and in the policies being adopted at medical schools and teaching hospitals. Just last week our partner at The Pew Charitable Trusts released best practices in conflict-of-interest policies.

    GSK’s announcement will send ripples through the entire pharmaceutical industry, and we hope that other major companies will also end the ...

    Full story

    Comments (0)

  • Moving COI Policies Up A Notch: New Recommendations from an Expert Task Force

    It’s no secret that medical device and pharmaceutical companies have had long-standing relationships with medical schools and teaching hospitals. And although fruitful collaborations with these companies, primarily for research and collaboration, should continue, some of these relationships have gone too far. Although many schools have significantly strengthened their conflict-of-interest policies that govern these relationships, industry still brings biased information into our nation’s medical education training grounds—places that should be steeped in evidence-based learning. One recent survey of medical schools, for example, found that up to half of medical students and residents reported receiving personal gifts from pharmaceutical companies, even in schools graded highly on the AMSA Scorecard.
     
    Conflict-of-interest policies, guidelines for how industry can (or cannot) interact with an institution, are key to preventing this industry overreach. There is evidence demonstrating that COI policies at medical schools can, in fact, impact prescribing behavior. One study showed that graduates from schools with strong COI policies prescribed antidepressants more rationally than graduates with weaker or no COI policies. 
     
    Today, The Pew Charitable Trusts, in partnership with an expert task force of leaders from academic medicine and other partners, including AMSA, released a set of 15 best practices for medical ...

    Full story

    Comments (0)

  • Advice as graduation approaches....

    To the Class of 2013,

    Congratulations on an incredible achievement; in a few short days or weeks you will be receiving your MD/DO degree and then embarking onto residency! While you undergo this transition, the field of medicine also is facing dramatic changes, both internally and externally. There has been increasing scrutiny on the objectivity of our judgement as physicians and how our relationships with industry can affect the trust relationship that is at the heart of the doctor-patient dyad.

    Patients are skeptical of our relationships with industry and are concerned that they may compromise our ability to render effective and cost conscious care. In fact, studies have shown that when exposed to industry interactions such as gifts (even pens!), drug samples, free meals, and travel, doctors are more likely to prescribe costly name-brand medications and less likely to prescribe the cheaper generic alternatives. You might see this as a deviation from the evidence-based prescribing methods you learned over the past four years, while patients may see it as an erosion of trust and a higher bottom line cost for medical care in a world of skyrocketing healthcare costs.

    If you can appreciate that industry interactions with medical professionals have ...

    Full story

    Comments (0)

  • Dollars for Doctors: Are Pharmaceutical Companies Paying Your Doctors?

    AMSA PharmFree Fellow Reshma Ramachandran joined a panel on American Law Journal to debate whether physicians should take money from pharmaceutical companies. They also discussed the recent GlaxoSmithKline settlement over "unsavory marketing practices" and its "unhealthy alliance with doctors," specifically Dr. Drew.

    Full story

    Comments (0)

  • Watch the PharmFree Scorecard Launch!

    On Thursday, March 8th, AMSA released the findings of the 2011-2012 PharmFree Scorecard.

    Watch the Webex now!

    And check out www.amsascorecard.org to see what your school got for a grade!

    Full story

    Comments (0)

  1. 1
  2. 2
  3. 3
  4. Next page

What is AMSA On Call?

AMSA On Call is the official blog of the American Medical Student Association. Join us as we discuss the hottest issues in health care. 

Save the Date

AMSA's 2015 Annual Convention
AMSA's 2015 Annual Convention

February 26 - March 1, 2015
Arlington, VA / Washington, DC

Current Campaigns

AMSA actively focuses on campaigns throughout the year that align with our organization's aspirations, mission and values.

The New Physician (TNP)

The New Physician MagazineRead AMSA's award-winning magazine & past issues.

Follow Us

Follow us on FaceBook Follow us on Twitter AMSA on YouTube AMSA RSS